Cargando…

Tarlatamab: a potential new option for recurrent small cell lung cancer

Detalles Bibliográficos
Autores principales:	Addeo, Alfredo, Banna, Giuseppe Luigi, Friedlaender, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413042/ https://www.ncbi.nlm.nih.gov/pubmed/37577302 http://dx.doi.org/10.21037/tlcr-23-215

Ejemplares similares

Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019)

Stepping in the right direction but still some ways to go
por: Addeo, Alfredo, et al.
Publicado: (2019)

Tarlatamab: the promising immunotherapy on its way from the lab to the clinic
por: Tang, Daolin, et al.
Publicado: (2023)

From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

COVID-19 and lung cancer: risks, mechanisms and treatment interactions
por: Addeo, Alfredo, et al.
Publicado: (2020)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
por: Friedlaender, Alex, et al.
Publicado: (2019)

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023)

Tracking the tail
por: Friedlaender, Alex, et al.
Publicado: (2020)

One more piece to SOLIDify our knowledge on the impact of SARS-CoV-2 in patients with cancer
por: Addeo, Alfredo, et al.
Publicado: (2022)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review
por: Thouvenin, Laure, et al.
Publicado: (2021)

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
por: Paz-Ares, Luis, et al.
Publicado: (2023)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

1393P Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy
por: Banna, G.L., et al.
Publicado: (2020)

The clinical fallout of organizational resilience in oncology during the pandemic
por: Addeo, Alfredo, et al.
Publicado: (2022)

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
por: Parekh, Jay, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
por: Addeo, Alfredo, et al.
Publicado: (2019)

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
por: Mederos, Nuria, et al.
Publicado: (2020)

New potential targeted strategies in small cell lung cancer
por: de Toro, María, et al.
Publicado: (2023)

Drugging KRAS: current perspectives and state-of-art review
por: Parikh, Kaushal, et al.
Publicado: (2022)

Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer
por: Addeo, Raffaele
Publicado: (2021)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
por: Yamaguchi, Teppei, et al.
Publicado: (2019)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

The Role and Impact of Minimal Residual Disease in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2021)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Learning from the past to design better trials in second-line treatment for mesothelioma patients
por: Addeo, Alfredo, et al.
Publicado: (2018)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Neoadjuvant Immunotherapy: A Promising New Standard of Care
por: Boydell, Emma, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hqi39871rmpaimhvntbopg2lg0